Abstract Library

#4343 Ga68-DOTATATE imaging on a state-of-the-art total-body PET/CT scanner with reducing administered activity

Introduction: Long-field of view PET/CT scanners allows total body scanning resulting higher sensitivity than traditional PET/CT scanners offering possible lower dose and faster scans.

Conference:

Presenting Author: Santillan N

Authors: Navalkissoor S, Santillan N, Chowdhury A, Ferreira B, Toumpanakis C,

Keywords: SSR, Ga68 DOTATATE, Neuroendocrine tumour, Quadra,

#3491 Renal uptake monitoring during different cycles of 90Y-DOTATOC therapy based on 111In and 90Y SPECT imaging

Introduction: Unresectable or borderline resectable WHO G1/G2 P-NETs patients with limited liver disease are treated with 6 90Y-DOTATOC therapy cycles within a clinical protocol. Kidney dosimetry is performed at first cycle. Assuming equal absorbed dose for all cycles, cycles are reduced if cumulative dose exceeds kidney toxicity limits.

Conference:

Presenting Author: d'Arcangelo M

Authors: d'Arcangelo M, Botta F, Ferrari M, Ghisini R, Fodor C,

Keywords: dosimetry, PRRT, 90Y,

#1787 Towards Personalizing PRRT with [177Lu]-Dotatate to Minimise Renal Toxicity in Neuroendocrine Tumour Patients

Introduction: The kidney is a dose-limiting organ in [177Lu]-Dotatate PRRT (Lutate) and thus renal function is an important prescribing consideration for NET patients. The effect of baseline renal function on kidney absorbed dose is unclear.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Eslick E, Hayes A, Willowson K, Ryu H, Hennessy T,

Keywords: peptide receptor radionuclide therapy, Lutate, renal function, kidney absorbed dose,

#1156 Characterisation, Measurement and Biodistribution of an Improved Formulation of [Lu-177]-Octreotate

Introduction: Lu-177 can be made with high specific activity and no other isotopes of lutetium present, referred to as “no carrier added” (nca) Lu-177. We have radiolabelled DOTA-conjugated peptide DOTA‐(Tyr3)‐octreotate (Auspep, Melb., AUS) with nca Lu-177 (“nca-LuTATE”) and used it in over 30 administrations in NETs patients.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Bailey D

Authors: Bailey D, Willowson K, Hennessy T, Schembri G, Snowdon G,

Keywords: lutetium, dosimetry, biodistribution, effective dose,

#1141 New Hybrid SPECT-CT Modality for Imaging Purposes in Patients with Medullary Thyroid Cancer (MTC)

Introduction: Loco-regional lymph node and distant metastases are found very often in patients with MTC of less than 1 cm. There is not good MTC response to systemic chemotherapy or to external been radiotherapy. Radical thyroidectomy is the main method of therapy. Early diagnosis and correct N/M-staging are extremely important for the management of MTC. New hybrid SPECT-CT γ-cameras allow the fusion of anatomical and functional modalities. SPECT-CT is used in order to optimize somatostatin-receptor scintigraphic protocols.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Sergieva S

Authors: Sergieva S, Pandev R, Robev B, Fakirova A,

Keywords: MTC, somatostatin SPECT-CT image,